Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the ...

Now, it’s worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Also Read: UK’s Health Agency Endorses Pfizer’s Blood Cancer Combo Therapy As First For ... amounting to 8.8 billion yen.

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...

With Virgin shares holding nicely at cruising altitude, is now the right time for private oncology drug developer Qbiotics to ...

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

Income-focused investors actively pursuing high yielders should understand what they stand to sacrifice by reaching for a ...

The antibody discovery market is expanding, driven by the increasing incidence of chronic conditions such as cancer, diabetes, and cardiovascular and ...